Diabetes has become a greater threat to the overall population’s health as society urges a fast-paced lifestyle. With people ingesting more and unhealthier foods, diabetes has become a prevalent enemy to our bodies. In fact, as of 2003, the prevalence rate in Korea is 5.92% which is approximately 2.86 million patients. Experts even estimated that the total number of diabetes patients could reach 4 million if we include those who haven’t received treatment and those who are in the initial pre-diabetes stage. With these statistics alone, it’s safe to say that diabetes is a clear danger to everyone who isn’t health-conscious. This is why the company, NDD or Nano Diagnostics & Devices, has created a specialized tool for sensing diabetes.
As a company, NDD serves to distribute new medicinal technology and devices to advance the science and medicine field. They’ve created a sensor called the SMART ALBU, which doesn’t require the user to collect blood in order to diagnose them for diabetes. Instead, the substitute for blood would be the patient’s saliva. The device also guarantees clear results in a short amount of time, and it can be used both at home and in the hospital.
Checking blood sugar through the blood can be a risk of infection. Since saliva is made from body fluids, it represents an abnormality of the body. The saliva test is easier to collect than the blood test, there is no low cost and no risk of infection.
How the SMART ALBU works is that it acts as a semiconductor for CNT-FET manufacturing. It also contains a patented material that attaches ABA to CNT then there’s a separate process for minimizing protein assay. It beats its competitor, the A1C, due to its prevention of hyperglycemic shock and its reliable diagnosis of diabetes symptoms. Furthermore, SMART ALBU isn’t affected by changes in blood-sugar levels caused by food consumption, so it can serve as an important index for long-time blood sugar control results. Also, compared to the A1C, glycated albumin has a shorter half-life and is therefore more preferred. It’s also come to attention that certain groups cannot use A1C including pregnant women, AIDS patients, growing infants and children, dialyzed patients, and patients with a blood disorder. On the other hand, SMART ALBU doesn’t exclude any of these groups from using it. In fact, the American Healthcare Association, the American Diabetes Association, and the Ministry of Health have recently published research results showing that albumin glycosylation concentration can indicate accurate average blood sugar levels for all groups.
Besides the fact that the patient doesn’t have to draw blood, the overall benefit of using SMART ALBU is that it determines the progression of the diabetes and the probability of any future complications. It’s a portable tester, and it’s safe to use on children and the elderly. SMART ALBU also doesn’t require a marker to obtain clear results. Experts expect that the albumin test will be widely-adopted in the coming months.
Researchers and facilities have spent millions of dollars on outdated technology to diagnose and treat diabetes. Although traditional methods of treatment are still reliable, the field of science and medicine has always left room for improvement. This is why NDD has created SMART ALBU, which doesn’t completely disregard older methods but it serves to improve them. Rather than having patients consistently drawing blood, SMART ALBU is a painless alternative and it showcases even clearer results. With technology quickly advancing, disease and illness can be promptly treated at rapid rates. While these innovations can’t completely exterminate all ailments, they can definitely make them less of a threat to our society.
▲ NDD, Inc
▲ Brand Name: NDD
▲ CEO : Myeong Hoon Lee
▲ www.ndd-inc.com
▲ E-mail : mhlee@ndd-inc.com
▲ T : +82-54-465-8207
Ralph Suh, Julie Kim
K-Herald Korea
(Los Angeles Times Advertising Supplement)
